Novartis Goes First

Novartis' CAR-T cell therapy is now the first of its kind to be approved by the FDA, reports Marketwatch. The pharmaceutical company's Kymriah, the first gene therapy available in the US, will be accessible to young people up to age 25 with a form of acute lymphoblastic leukemia.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.